IgE is the Immunoglobulin Responsible for Allergic Reactions
IgE (Immunoglobulin E) is the specific antibody class that mediates allergic reactions to allergens. This antibody binds to high-affinity receptors (FcεRI) on mast cells and basophils, and when cross-linked by allergen exposure, triggers the immediate release of inflammatory mediators like histamine that cause allergic symptoms 1, 2.
Mechanism of IgE-Mediated Allergic Response
The allergic cascade operates through a specific sequence:
- Sensitization Phase: Initial allergen exposure in atopic individuals leads to production of allergen-specific IgE antibodies 3
- Binding Phase: These IgE antibodies bind to FcεRI (high-affinity) and FcεRII/CD23 (low-affinity) receptors on effector cells and antigen-presenting cells 1, 3
- Activation Phase: Subsequent allergen exposure cross-links the receptor-bound IgE, triggering immediate mediator release from mast cells and basophils 2, 4
A critical structural requirement: IgE requires a single N-linked oligomannose glycan at asparagine-394 (N394 in humans, N384 in mice) for biological activity. Without this glycosylation, IgE cannot bind FcεRI and cannot trigger allergic reactions 5.
Clinical Implications
Immediate and Late-Phase Reactions
IgE drives both phases of allergic responses:
- Immediate phase: Occurs within minutes through histamine and other mediator release from basophils and mast cells 1
- Late-phase response: Develops hours later through recruitment of eosinophils, mast cells, and other inflammatory cells to affected tissues 1
IgE Levels and Clinical Disease
An important clinical caveat: IgE levels do not directly correlate with symptom severity. During allergen immunotherapy, specific IgE levels initially increase, then gradually decrease, but clinical improvement occurs before IgE reduction and is not dependent on decreased IgE levels 2. Some patients improve despite persistently elevated IgE, while others with low IgE can still experience severe reactions 2.
Role of Other Immunoglobulins
While IgE is the primary culprit, other antibodies play modulating roles:
- IgG (especially IgG4): Increases during immunotherapy and can block IgE-dependent reactions by competing for allergen binding and preventing IgE-facilitated antigen presentation 1
- IgA: Also increases with immunotherapy, though its protective properties are less well-defined 2
These blocking antibodies recognize different epitopes than IgE and do not naturally interfere efficiently with allergic inflammation, but can be therapeutically induced through allergen immunotherapy 3.
Therapeutic Targeting
The central role of IgE makes it an ideal therapeutic target: